75/100BCardinal Health financials
Yes. Cardinal Health earned 1.82B USD of net income over the last twelve months, 0.7% of its revenue. It made a profit in 39 of its 41 fiscal years since 1986. Its last loss was in fiscal year 2022.
- Revenue (TTM)
- 257.75B USD
- Net income (TTM)
- 1.82B USD
- Free cash flow (TTM)
- 4.90B USD
- Cash and short-term investments
- 5.26B USD
- Total debt
- 8.82B USD
- Shareholders' equity
- -3.03B USD
Cash, debt and equity as of 30 Sept 2026.
Cardinal Health earnings
Revenue
EPS
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2028 | 3.81 | — | — | — | 66.72B | — | — | — | |
| Q2 FY2028 | 3.50 | — | — | +12.11% | 71.62B | — | — | +4.86% | |
| Q1 FY2028 | 3.33 | — | — | +2.01% | 70.02B | — | — | +3.71% | |
| Q2 FY2027 | 3.12 | — | — | +18.63% | 68.30B | — | — | +4.07% | |
| Q1 FY2027 | 2.94 | 3.26 | +10.88% | +27.84% | 66.67B | 67.51B | +1.27% | +5.47% | |
| Q4 FY2026 | 2.42 | 2.91 | +20.25% | +39.90% | 65.15B | 63.67B | -2.27% | +5.84% | |
| Q3 FY2026 | 2.79 | 3.17 | +13.62% | +34.89% | 62.10B | 60.94B | -1.87% | +11.05% | |
| Q2 FY2026 | 2.34 | 2.63 | +12.39% | +36.27% | 65.08B | 65.63B | +0.84% | +18.75% | |
| Q1 FY2026 | 2.18 | 2.55 | +16.97% | +35.64% | 59.24B | 64.01B | +8.05% | +22.44% | |
| Q4 FY2025 | 2.04 | 2.08 | +1.96% | +13.04% | 60.89B | 60.16B | -1.20% | +0.49% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2029 | 15.59 | — | — | +10.77% | 297.40B | — | — | +5.56% |
| FY2028 | 14.08 | — | — | +11.96% | 281.74B | — | — | +6.00% |
| FY2027 | 12.57 | — | — | +11.65% | 265.81B | — | — | +4.55% |
| FY2026 | 10.78 | 11.26 | +4.48% | +36.65% | 255.87B | 254.25B | -0.63% | +14.23% |
| FY2025 | 8.20 | 8.24 | +0.52% | +10.31% | 223.26B | 222.58B | -0.30% | -1.94% |
| FY2024 | 5.26 | 7.47 | +42.11% | +28.57% | 224.45B | 226.99B | +1.13% | +10.72% |
| FY2023 | 5.74 | 5.81 | +1.17% | +14.82% | 204.30B | 205.01B | +0.35% | +13.04% |
Cardinal Health growth and profitability
Full income statement- Revenue (TTM)
- 257.75B USD
- Net income (TTM)
- 1.82B USD
- Gross margin
- 3.90%
- Operating margin
- 1.05%
- Net margin
- 0.71%
Revenue / Net income
How Cardinal Health makes its money
FY2026, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2026, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Cardinal Health revenue breakdown
By product
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Pharmaceutical Member | 234.83B | 92.3% | +14.8% |
| GMPD | 12.72B | 5.0% | +0.7% |
| Other Operating | 6.79B | 2.7% | +26.2% |
By region
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| United States | 252.64B | 99.3% | +14.3% |
| Non-US | 1.71B | 0.7% | +2.2% |
Operating and free cash flow
Full cash flow statementCardinal Health financial health
Full balance sheet- Cash and short-term investments
- 5.26B USD
- Total debt
- 8.82B USD
- Net cash
- -3.55B USD
- Free cash flow (TTM)
- 4.90B USD
- Current ratio
- 0.88
- Piotroski score
- 7 / 9
- Altman Z-score
- 5.02
Cash, debt and free cash flow
Assets, liabilities and equity
Cardinal Health valuation
- Price to earnings ratio (TTM)
- 34.97
- Forward P/E (FY2027)
- 21.62
- Price to sales (TTM)
- 0.24
- EV / EBITDA (TTM)
- 18.59
Capital structure
Valuation over time
Cardinal Health against its own history
Each figure in the latest fiscal year against the same figure from FY2022 to FY2026: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Cencora, McKesson, and Henry Schein, the US Medical - Distribution companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Above its median35.021.4198.7
- Gross marginHighest in 5 years3.8%3.3%3.8%Against its peers: 3 of 4Peers' median 4.1%
- Operating marginHighest in 5 years1.0%-0.3%1.0%Against its peers: 4 of 4Peers' median 1.6%
- Net marginAbove its median0.7%-0.5%0.7%Against its peers: 4 of 4Peers' median 1.2%
- Free cash flow marginHighest in 5 years1.8%0.8%1.8%Against its peers: 2 of 4Peers' median 1.3%
- Revenue growthHighest in 5 years14.2%-1.9%14.2%Against its peers: 1 of 4Peers' median 5.0%
- EPS growthBelow its median12.1%-260.6%173.8%Against its peers: 3 of 4Peers' median 49.2%
- Debt to EBITDABelow its median2.86×2.86×105.55×Against its peers: 3 of 4Peers' median 1.84×
- Current ratioLowest in 5 years0.880.881.08Against its peers: 3 of 4Peers' median 0.94
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Cardinal Health dividends
- Annual dividend
- 2.06 USD
- Dividend yield (indicated)
- 0.76%
- Payout ratio
- 26.42%
- Years of dividend growth
- 40
- Frequency
- Quarterly
- Last payment
- 0.52 USD
- Last ex-dividend date
- 1 Oct 2026
- Last payment date
- 15 Oct 2026
Dividends per share
Cardinal Health ownership
- Institutions
- 88.34%
- Institutional holders
- 1,550 (+62)
- Free float
- 99.76%
Who owns the shares
Shares free to trade
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q3 2026 | 0 | 31 | 482.51K | 480.42K |
| Q2 2026 | 0 | 0 | 381.00 | 0.00 |
| Q1 2026 | 0 | 4 | 3.98K | 10.99K |
| Q4 2025 | 0 | 0 | 12.37K | 1.95K |
Shares outstanding
Common questions about Cardinal Health's financials
Source: Financial Modeling Prep